Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection.

Yamamoto Y, Izumikawa K, Hashiguchi K, Fukuda Y, Kobayashi T, Kondo A, Inoue Y, Morinaga Y, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yanagihara K, Kohno S.

J Infect Chemother. 2012 Apr;18(2):241-6. doi: 10.1007/s10156-012-0397-4. Epub 2012 Mar 8.

PMID:
22398881
2.

Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study.

Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, Oda S, Akiyama N, Miyao N, Yoshida M, Yukioka T, Soma K, Ohyashiki K, Suzuki Y, Arai T, Ikegami K, Ichiwata T, Otsuka Y, Kobayashi M, Totsuka K, Sunakawa K; ABK Dose Finding Study Group.

J Infect Chemother. 2013 Feb;19(1):128-37. doi: 10.1007/s10156-012-0519-z. Epub 2012 Dec 22.

PMID:
23263188
3.

[Clinical efficacy of arbekacin on MRSA pneumonia].

Kawashima T, Shishibara T, Nakamura H, Kuriyama T, Kanno S, Watanabe M, Kikuchi N, Kunitomo F, Yamagishi F, Mizutani F, et al.

Jpn J Antibiot. 1994 Jun;47(6):741-50. Japanese.

PMID:
8072183
4.

Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9.

5.

Intrathoracic irrigation with arbekacin for methicillin-resistant Staphylococcus aureus empyema following lung resection.

Ueno T, Toyooka S, Soh J, Miyoshi K, Sugimoto S, Yamane M, Oto T, Miyoshi S.

Interact Cardiovasc Thorac Surg. 2012 Sep;15(3):437-41. doi: 10.1093/icvts/ivs285. Epub 2012 Jun 20.

6.

[Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group].

Morimoto K, Nakatani S, Kaji M, Kinoshita H, Fujimoto M, Hirata S, Ueda T, Tamate S, Yamazaki O.

Jpn J Antibiot. 1994 Jun;47(6):826-36. Japanese.

PMID:
8072193
7.

[Clinical efficacy of arbekacin on MRSA infections].

Ichiyama S, Shimokata K.

Jpn J Antibiot. 1994 Jun;47(6):731-5. Japanese.

PMID:
8072181
8.
9.

[Clinical efficacy of arbekacin in patients with methicillin-resistant Staphylococcus aureus infections. Research Group of MRSA Forum].

Nasuhara K, Takatsuka K, Takatsuka N, Teraoka M, Tokita S, Shinohara M, Azuma E, Saijo N, Sone H, Saito I, et al.

Jpn J Antibiot. 1994 Jun;47(6):720-30. Japanese.

PMID:
8072180
10.

[An evaluation study on arbekacin for MRSA-infectious diseases including pneumonia, septicemia and others].

Odagiri S, Sumitomo M, Takahashi K, Matsumoto F, Sakurai I, Imai T, Yoshikawa K, Ito A, Sugiyama M, Suzuki M, et al.

Jpn J Antibiot. 1994 Jun;47(6):751-62. Japanese.

PMID:
8072184
11.

[Clinical efficacy of arbekacin in deep MRSA infection. Including follow-up study after the termination of chemotherapy].

Kuwabara M, Konishi F, Yokoyama T, Kodama T, Santoh T, Nakai S, Miyoshi N, Kurimura T, Miyazawa T, Arita K, et al.

Jpn J Antibiot. 1994 Jun;47(6):771-80. Japanese.

PMID:
8072186
12.

Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K.

Antimicrob Agents Chemother. 2006 Nov;50(11):3754-62.

13.

The usefulness of arbekacin compared to vancomycin.

Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29.

14.

[Clinical investigation of arbekacin sulfate based on Cmax/MIC].

Kimura M, Yamagishi Y, Kawasumi N, Mikamo H.

Jpn J Antibiot. 2012 Aug;65(4):263-9. Japanese.

PMID:
23259256
15.

[Analysis of factors in selecting anti-methicillin-resistant Staphylococcus aureus drugs by doctors].

Hayashi H, Matsuzaki T, Saito A, Aoyama T, Matsumoto Y.

Yakugaku Zasshi. 2008 Jan;128(1):81-7. Japanese.

17.

[Nationwide investigation in Japan of the status of MRSA infections and usefulness of arbekacin].

Hayashi I, Inoue M, Hashimoto H.

Jpn J Antibiot. 1994 Jun;47(6):595-605. Japanese.

PMID:
8072167
18.

Clinical efficacy of arbekacin for Gram-negative bacteria.

Hamada Y, Tamura K, Koyama I, Kuroyama M, Yago K, Sunakawa K.

J Infect Chemother. 2011 Dec;17(6):876-9. doi: 10.1007/s10156-011-0262-x. Epub 2011 Jun 11. Erratum in: J Infect Chemother. 2011 Dec;17(6):880-1.

PMID:
21667069
19.

Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin.

Otsuka T, Tanaka A, Suemaru K, Inoue T, Nishimiya T, Murase M, Araki H.

J Clin Pharm Ther. 2008 Jun;33(3):227-35. doi: 10.1111/j.1365-2710.2008.00905.x.

PMID:
18452409
20.

[Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man].

Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M.

Jpn J Antibiot. 1994 Jun;47(6):676-92. Japanese.

PMID:
8072176
Items per page

Supplemental Content

Write to the Help Desk